Brind.

Gilead Sciences expanded a partnership to co-develop next-generation CAR-T cell therapies.

1 report, 1 independent Updated Aug 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Gilead Sciences Arcellx

Keep exploring

The entities involved

Gilead Sciences
American company
- Amgen and Gilead Sciences are two companies that compete within the biotech industry.Sun 11:22
- Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Fri 16:08
Arcellx
Biotechnology Company

Nothing else this week.

Related events

Gilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.Thu 12:56

Coverage

Newest first; wire copies grouped

Aug 28Insider MonkeyArcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial We recently published 11 Best Cancer Stocks to Buy Right Now. Arcellx, Inc. stands sixth among them. Arcellx, Inc. (NASDAQ:ACLX) is a bio